Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Second Autologous Stem Cell Transplant As Salvage Therapy in Multiple Myeloma - the Oregon Health and Science University Experience

Derek Galligan, MD, Staci Williamson, MS, Jessie Myers, Rebecca W. Silbermann, MD, Eva Medvedova, MD, Levanto Schachter, DO,MS, Sarah J. Nagle, MD, Andy Chen, MDPhD, Richard T. Maziarz, MD

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-142770

Published: 2020

Journal Articles

Endothelial Injury Markers and Central Nervous System Damage-Associated Proteins in Immune Effector Cell-Associated Neurotoxicity Syndrome

Benjamin K Elstrott, BA, Sarah J. Nagle, MD, Caleb Price, BS, Luz Mejia-Flores, Nathan Beird, H. E. Hinson, MD MCR

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-139011

Published: 2020

Journal Articles

Efficacy and Safety of Tisagenlecleucel in Adult Patients with Relapsed/Refractory Follicular Lymphoma: Interim Analysis of the Phase 2 Elara Trial

Nathan H Fowler, MD, Michael Dickinson, DMed Sci, Martin Dreyling, MD, Joaquin Martinez-Lopez, MD, Arne Kolstad, MD PhD, Jason P Butler, MBBS, MMedSc, FRACP, FRCPA, Monalisa Ghosh, MD, Leslie L. Popplewell, MD FACP, Julio C. Chavez, MD, Emmanuel Bachy, MD PhD, Koji Kato, MD PhD, Hideo Harigae, MD PhD, Marie José Kersten, MD PhD, Charalambos Andreadis, MD, Peter A. Riedell, MD, P. Joy Ho, MB.BS. (Hons), D.Phil (Oxon), FRACP, FRCPA, FFSc(RCPA), Jose Antonio Pérez-Simón, MD, Sarah J. Nagle, MD, Loretta J. Nastoupil, MD, Bastian von Tresckow, MD, Andres JM Ferreri, MD, Takanori Teshima, MD, Piers Patten, MD PhD, Joseph P. McGuirk, DO, Andreas Petzer, MD, Fritz C. Offner, MD PhD, Andreas Viardot, Professor Dr, Pier Luigi Zinzani, MD, Ram Malladi, MBBS(Lond), MRCP(UK), FRCPath, Lida Bubuteishvili Pacaud, MD, Alessandra Forcina, MD, Aiesha Zia, Stephen J. Schuster, MD, Catherine Thieblemont, MD PhD

Blood (2020) 136 (Supplement 1): 1–3.

https://doi.org/10.1182/blood-2020-138983

Published: 2020

Journal Articles

Current Selection Patterns, Toxicities and Outcomes of Pre-Transplant Salvage Treatment Regimens in Patients with Relapsed/Refractory Hodgkin Lymphoma: Results of a Multicenter Retrospective Analysis

Jakub Svoboda, MD, Hatcher J. Ballard, BS, Steven M. Bair, MD, Rahul Banerjee, MD, Charalambos Andreadis, MD, Tatyana A. Feldman, MD, Elizabeth L. McCarthy, MSN, RN, Niloufer Khan, MD, Alison J. Moskowitz, MD, Victor M. Orellana-Noia, MD, Craig A. Portell, MD, Sarah J. Nagle, MD, Sunita Dwivedy Nasta, MD, Daniel J. Landsburg, MD, Stefan K. Barta, MD MRCP, MS, Elise A. Chong, MD, Stephen J Schuster, MD

Blood (2019) 134 (Supplement_1): 2855.

https://doi.org/10.1182/blood-2019-123741

Published: 2019

Journal Articles

Comorbidities Predict Inferior Survival in Patients Receiving CAR T-Cell Therapy for Relapsed/Refractory DLBCL: A Multicenter Retrospective Analysis

Adam S. Kittai, MD, Max J. Gordon, MD, Agrima Mian, MBBS, MD, Lindsey Fitzgerald, MD, Jennifer Bishop, Deborah M. Stephens, DO, Sarah J. Nagle, MD, Brian T. Hill, MD, Alexey Danilov, MD PhD

Blood (2019) 134 (Supplement_1): 780.

https://doi.org/10.1182/blood-2019-124694

Published: 2019

Journal Articles

The Impact of Autoimmune Disease on Clinical Outcomes of Patients with DLBCL and FL

Sarah J. Nagle, MD, Nirav N. Shah, MD, Alexis Ogdie, MD, Daniel J. Landsburg, MD, Anthony Mato, MDMSCE, Sunita Dwivedy Nasta, MD, Stephen J. Schuster, MD, Jakub Svoboda, MD

Blood (2014) 124 (21): 2974.

https://doi.org/10.1182/blood.V124.21.2974.2974

Published: 2014

Journal Articles

The Role Of PET Imaging For Predicting Treatment Failure In Primary Mediastinal B-Cell Lymphoma

Sarah J. Nagle, MD, Elise A. Chong, MD, Seble Chekol, MD, Nirav N. Shah, MD, Sunita D. Nasta, MD, Eli Glatstein, MD, John P. Plastaras, MD PhD, Drew Torigian, MD, Stephen J. Schuster, MD, Jakub Svoboda, MD

Blood (2013) 122 (21): 4302.

https://doi.org/10.1182/blood.V122.21.4302.4302

Published: 2013

Journal Articles

Outcomes of Patients with Refractory/Relapsed Diffuse Large B-Cell Lymphoma Who Progress After Autologous Stem Cell Transplantation in the Rituximab Era.

Sarah J. Nagle, MD, Kaitlin Woo, Rosemarie Mick, MS, Stephen J. Schuster, MD, Sunita D. Nasta, MD, Edward A. Stadtmauer, MD, Jakub Svoboda, MD

Blood (2012) 120 (21): 2689.

https://doi.org/10.1182/blood.V120.21.2689.2689

Published: 2012

NARROW

Second Autologous Stem Cell Transplant As Salvage Therapy in Multiple Myeloma - the Oregon Health and Science University Experience

Endothelial Injury Markers and Central Nervous System Damage-Associated Proteins in Immune Effector Cell-Associated Neurotoxicity Syndrome

Efficacy and Safety of Tisagenlecleucel in Adult Patients with Relapsed/Refractory Follicular Lymphoma: Interim Analysis of the Phase 2 Elara Trial

Current Selection Patterns, Toxicities and Outcomes of Pre-Transplant Salvage Treatment Regimens in Patients with Relapsed/Refractory Hodgkin Lymphoma: Results of a Multicenter Retrospective Analysis

Comorbidities Predict Inferior Survival in Patients Receiving CAR T-Cell Therapy for Relapsed/Refractory DLBCL: A Multicenter Retrospective Analysis

The Impact of Autoimmune Disease on Clinical Outcomes of Patients with DLBCL and FL

The Role Of PET Imaging For Predicting Treatment Failure In Primary Mediastinal B-Cell Lymphoma

Outcomes of Patients with Refractory/Relapsed Diffuse Large B-Cell Lymphoma Who Progress After Autologous Stem Cell Transplantation in the Rituximab Era.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only